- Home
- / Edgewise Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Edgewise Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$34.5
2024-10-29
Market Capitalization
$3.2 B
2024-10-29
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|
| General and administrative expense | 17.6M | 23.5M | 31.9M | 40.0M |
| Operating expense total | 71.7M | 114.4M | 158.8M | 191.4M |
| EBIT | (71.7M) | (114.4M) | (158.8M) | (191.4M) |
| Interest income | 4.0M | 14.2M | 25.0M | 23.6M |
| Pre tax profit | (167.8M) | |||
| Income tax expense | 4.0K | |||
| Net Income | (67.6M) | (100.2M) | (133.8M) | (167.8M) |
| EPS | (1.3) | (1.6) | (1.4) | (1.6) |